Declining Guillain-Barre Syndrome after Campylobacteriosis Control, New Zealand, 1988-2010

被引:40
作者
Baker, Michael G. [1 ]
Kvalsvig, Amanda
Zhang, Jane
Lake, Rob [2 ]
Sears, Ann
Wilson, Nick
机构
[1] Univ Otago, Dept Publ Hlth, Wellington 6242, New Zealand
[2] Inst Environm Sci & Res, Christchurch, New Zealand
关键词
INFLUENZA; INFECTIONS; DISEASE; VIRUS; RATES;
D O I
10.3201/eid1802.111126
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infection with Campylobacter spp. commonly precedes Guillain-Barre syndrome (GBS). We therefore hypothesized that GBS incidence may have followed a marked rise and then decline in campylobacteriosis rates in New Zealand. We reviewed records for 1988-2010: hospitalization records for GBS case-patients and campylobacteriosis case-patients plus notifications of campylobacteriosis. We identified 2,056 first hospitalizations for GBS, an average rate of 2.32 hospitalizations/100,000 population/year. Annual rates of hospitalization for GBS were significantly correlated with rates of notifications of campylobacteriosis. For patients hospitalized for campylobacteriosis, risk of being hospitalized for GBS during the next month was greatly increased. Three years after successful interventions to lower Campylobacter spp. contamination of fresh poultry meat, notifications of campylobacteriosis had declined by 52% and hospitalizations for GBS by 13%. Therefore, regulatory measures to prevent foodborne campylobacteriosis probably have an additional health and economic benefit of preventing GBS.
引用
收藏
页码:226 / 233
页数:8
相关论文
共 33 条
  • [11] Guillain-Barre syndrome -: A prospective, population-based incidence and outcome survey
    Chiò, A
    Cocito, D
    Leone, M
    Giordana, MT
    Mora, G
    Mutani, R
    [J]. NEUROLOGY, 2003, 60 (07) : 1146 - 1150
  • [12] H1N1 vaccine safety monitoring: beyond background rates
    DeStefano, Frank
    Tokars, Jerome
    [J]. LANCET, 2010, 375 (9721) : 1146 - 1147
  • [13] HADDEN RD, 2001, S SER SOC APPL MICRO, V30, pS145
  • [14] Preceding infections, immune factors, and outcome in Guillain-Barre syndrome
    Hadden, RDM
    Karch, H
    Hartung, HP
    Zielasek, J
    Weissbrich, B
    Schubert, J
    Weishaupt, A
    Cornblath, DR
    Swan, AV
    Hughes, RAC
    Toyka, KV
    [J]. NEUROLOGY, 2001, 56 (06) : 758 - 765
  • [15] Estimating community incidence of Salmonella, Campylobacter, and Shiga toxin-producing Escherichia coli infections, Australia
    Hall, Gillian
    Yohannes, Keflemariam
    Raupach, Jane
    Becker, Niels
    Kirk, Martyn
    [J]. EMERGING INFECTIOUS DISEASES, 2008, 14 (10) : 1601 - 1609
  • [16] Immunotherapy for Guillain-Barre syndrome:: a systematic review
    Hughes, Richard A. C.
    Swan, Anthony V.
    Raphael, Jean-Claude
    Annane, Djillali
    van Koningsveld, Rinske
    van Doorn, Pieter A.
    [J]. BRAIN, 2007, 130 : 2245 - 2257
  • [17] Jacobs BC, 2008, CAMPYLOBACTER, 3RD EDITION, P245
  • [18] Lymphoma and peripheral neuropathy: A clinical review
    Kelly, JJ
    Karcher, DS
    [J]. MUSCLE & NERVE, 2005, 31 (03) : 301 - 313
  • [19] Lake Rob, 2004, N Z Med J, V117, pU893
  • [20] Risk Ranking for Foodborne Microbial Hazards in New Zealand: Burden of Disease Estimates
    Lake, Robin J.
    Cressey, Peter J.
    Campbell, Donald M.
    Oakley, Elisabeth
    [J]. RISK ANALYSIS, 2010, 30 (05) : 743 - 752